Heat-shock proteins (HSPs) induce protective cytotoxic immune responses against tumour antigens. This property is related to their ability to bind to and to be internalized by DC (dendritic cells) before gaining access to the MHC class I processing pathway, a process called antigen cross-presentation. This process requires internalization of the antigen by DC via endocytic receptors. Owing to their particular immune properties, several studies were focused on the identification of HSP-binding elements on DC. We and others have reported that scavenger receptors are the main HSP-binding structures on human DC and have identified LOX-1 as one of these molecules. The binding of human Hsp70 to DC and the in vitro Hsp70-mediated antigen cross-presentation are inhibited by an anti-LOX-1 monoclonal antibody. In vivo, targeting LOX-1 with a tumour antigen using an anti-LOX-1 monoclonal antibody induces antitumour immunity. Thus scavenger receptors are certainly new promising targets for cancer immunotherapy.
Introduction
Exogenous antigens endocytosed by APC (antigen presenting cells) are mainly loaded into the MHC class II molecules for recognition by CD4+ T-cells, whereas, in contrast, endogenous antigens (self and viral proteins) are loaded in the MHC class I molecules for recognition by CD8+ T-cells. However, in some conditions, APC can present exogenous antigens in the MHC I molecules, a process called crosspresentation [1, 2] . Cross-presentation requires that exogenous antigens are internalized via endocytic receptors [3, 4] .
Among the APC, only DC (dendritic cells) are capable of priming both naive CD4+ and CD8+ T-cells to generate cytotoxic T-cell responses [5] . DC thus play a pivotal role between innate and adaptive immunity. Capture of exogenous antigens is a key step for DC to initiate an immune response. Thus to identify receptors expressed by DC and involved in antigen cross-presentation is of basic importance and currently a challenge in antitumour immunotherapy.
Antitumour immunotherapies aim to initiate protective cytotoxic responses against tumoral cells. Different strategies are currently investigated, such as cell-based therapies or humanized antibodies directed against tumour antigens. The identification of tumour-associated antigens and the existence of tumour-specific cytolytic T-lymphocytes suggested that initiating a protective antitumour immunoresponse is feasible. Numerous studies have been performed to propose new antitumoral vaccine strategies (recombinant virus, tumour cell-derived exosomes, RNA from tumoral cells etc.). Studies were focused on the identification of carrier proteins usable in antitumour vaccines. To be the most efficient, these vectors should selectively target and activate immature DC located in the periphery. Different molecules have been identified, such as bacteria proteins [6] , toxins and HSPs (heat-shock proteins).
HSPs are molecular chaperones that control the folding and prevent the aggregation of proteins. Tamura et al. [7] have demonstrated that tumour-derived HSPs initiate protective and tumour-specific cytolytic T-lymphocyte responses. Similar observations were made when tumour antigens were coupled or fused with HSPs [8] , demonstrating that an HSP acts as a vaccine carrier protein with exceptional adjuvant properties.
The cellular and molecular mechanisms involved in this particular biological property of HSPs have been partially identified: an HSP will non-covalently form a complex with tumour antigen-derived peptides [9, 10] and bind to DC before being internalized in a receptor-dependent manner [3, 11] . Several studies have thus been focused on the identification of HSP-binding structures expressed at the surface of APC. We used human Hsp70 as a tool to identify HSP-binding element(s) expressed on human DC.
Scavenger receptors (SRs) are the main HSP-binding elements expressed by DC
In vitro experiments showed that Hsp70 binds in a dosedependent manner on human monocyte-derived DC and peripheral blood myeloid DC. No binding was observed using tetanus toxoid, a molecule that is widely used as carrier protein in vaccines. Hsp70 also binds to other APCs, such as monocytes, macrophages and B cells, but not to T-cells. The binding of Hsp70 was saturable and partly competed by unlabelled Hsp70, thereby suggesting that Hsp70-binding structures exist on human APCs, as reported previously [3, 4, 11] . mBSA (maleylated BSA) is a ligand for numerous SRs [12] . mBSA, but not BSA, totally prevented Hsp70 binding to immature DC and, to a lesser extent, to macrophages, demonstrating that SR are the main Hsp70-binding structures on human DCs. SRs are cell-surface glycoproteins that bind modified lipoproteins and a broad spectrum of structurally unrelated ligands such as Ox-LDL (oxidized low-density lipoprotein), chemically modified LDL (acetylated LDL), apoptotic cells, bacteria and bacteriaderived cell-wall components (i.e. lipopolysaccharide and lipotechoic acid) [13] . Ox-LDL, acetylated LDL, apoliprotein B and poly [IC] prevented the binding of Hsp70 to human APCs. These results suggested that SRs are the main cellsurface-binding elements for HSPs on human APCs.
SR LOX-1 is a receptor for Hsp70 on human DCs and is involved in Hsp70-mediated antigen cross-presentation
To identify the SR(s) that bind Hsp70, we generated CHO (Chinese-hamster ovary) cell lines expressing recombinant human SR. Binding assays revealed that Hsp70 selectively bound to LOX-1-transfected CHO cells but not to the other SR tested, CD36, SRA-1, MARCO and CLA-1 [14] . The binding of Hsp70 to LOX-1-expressing CHO cells was prevented by different SR ligands, including mBSA, Ox-LDL and poly [IC] . Using an anti-LOX-1 mAb (monoclonal antibody) generated in the laboratory, we observed that LOX-1 is constitutively expressed by human monocytes, macrophages and immature DC, but not by CD83+ mature DC and T-lymphocytes. Interestingly, this neutralizing anti-LOX-1 mAb partly prevented the binding of Hsp70 to immature DC [14] . We next evaluated whether LOX-1 could be implicated in the Hsp70-mediated antigen cross-presentation by using ovalbumin as a whole tumour antigen model. Indeed, previous studies reported that HSPs initiate MHC class I-dependent immune responses against a whole antigen coupled or fused with HSPs [8] . In vitro assays showed that anti-LOX-1 mAb prevented Hsp70-mediated ovalbumin cross-presentation. We next evaluated whether targeting in vivo a tumour antigen to LOX-1 could elicit therapeutic and protective immune response against antigen-expressing tumour cells. Mice injected with ovalbumin-expressing tumour cells received ovalbumin coupled with the anti-LOX-1 mAb. Results showed that anti-LOX-1-ovalbumin plus adjuvant prevented tumour growth in mice, demonstrating that targeting in vivo a tumour antigen to LOX-1 triggers a protective antitumour immune response [14] .
Discussion

HSP-binding elements: LOX-1 and others
We demonstrated that LOX-1 is one of the HSP-binding elements expressed by human APCs and that LOX-1 is involved in Hsp70-mediated antigen cross-presentation, in vitro and in vivo [14] . Although partial with the neutralizing anti-LOX-1 mAb, the inhibition of Hsp70 binding to DC was total with SR ligands, suggesting that, in addition to LOX-1, other member(s) of the growing SR family are expressed on immature DC and involved in the binding of HSPs. Panjwani et al. [16] implicated the class B SR (CD36) in gp96 binding to APCs. Recently, Berwin et al. [17] reported that SR-A is involved in the binding of gp96 to murine APCs and in the gp96-mediated peptide representation. In contrast, we failed to detect Hsp70 binding to human CD36 and SRA-1 [14] . These differences could result from the HSPs used (gp96 versus Hsp70) and the origin of cells (human versus mouse). Additional experiments are required to respond to these questions.
Several studies have focused on the identification of HSPbinding elements expressed on APCs. Binder et al. [18] reported that CD91, the α 2 -macroglobulin receptor, is an HSP receptor expressed by APCs. However, additional studies showed that (i) CD91 is poorly expressed by DC compared with macrophages when both cell types bind in a similar manner to HSPs [14] , and (ii) that α 2 -macroglobulin did not inhibit the binding of gp96 on APCs [19] , suggesting the existence of other HSP-binding structures. Other studies reported that CD40 is involved in the binding and internalization by APCs of mycobacterial and human Hsp70 [20, 21] . Interestingly, this CD40-mediated activation of APCs induced by Hsp70 triggers the production of numerous chemokines [21] . However, to the best of our knowledge, CD40 has not been shown to be involved in the HSP-mediated antigen cross-presentation.
SRs in innate immunity and adaptive immunity
DCs containing antigens and macrophages play a key role at the interface between innate and adaptive immunity. They express numerous receptors involved in the recognition and endocytosis of a large number of pathogens, such as mannose receptor and SRs [22] . SRs can bind modified self (such as extracellular HSPs and apoptotic cells) and non-self (such as bacteria-derived cell-wall components). LOX-1 was initially identified as an Ox-LDL receptor. Recent studies show that it also binds nucleic acids, phospholipids, as well as Grampositive and Gram-negative bacteria. These results show, as reported for several SRs, that LOX-1 also binds modified self and non-self [15] . Thus the observation that most of the HSP-binding structures identified so far (CD91, LOX-1 and SRA-1) are members of the two related multiligand lipoprotein receptor families is in agreement with the hypothesis that innate cells have evolved to recognize a broad spectrum of danger signals with a restricted number of structures [5, 22, 23] . On the basis of this information, the binding and internalization of 'extracellular' HSPs via SRs makes sense, as it reflects recognition of a cellular damage that can be recognized as a potential danger that must be retrieved from the extracellular milieu. However, whether HSPs activate APCs, and consequently may initiate an immune response against a self-component, remains unclear. Indeed, DC have to be activated to present efficiently antigens to T-cells. Different molecules, such as CD14, CD40 and members of the TLR family, have been reported to be involved in the HSPmediated APC activation [21, 24, 25] . However, the ability of HSPs to activate innate cells by themselves remains debated as previous studies reported that endotoxin-free HSP do not activate APCs [26] . Even if endothelial cells can be activated in a LOX-1-dependent manner, we did not analyse whether the binding of Hsp70 to LOX-1 activates APCs. Collectively, the HSP-induced signalling in APCs, if any, appears complex and may involve different molecules; additional experiments are required to determine whether and how HSP activate APCs via SRs.
We have shown that targeting a tumour antigen in vivo to LOX-1 induces a protective antitumoral immune response [14] . It is interesting to underline that previous studies have already reported that targeting a vaccine antigen to SR may induce protective immune responses as maleylation of an antigen results in both MHC class I and class II antigen presentation in vitro [12, 27] .
In conclusion, recent studies have shown that SRs, among them LOX-1 and SRA-1, are involved in the HSP-mediated trafficking of exogenous antigen towards the MHC class I pathway and are involved in the initiation of protective antitumour immunity.
